CN114085900B - 与遗传性肾小球疾病相关的突变基因及其应用 - Google Patents

与遗传性肾小球疾病相关的突变基因及其应用 Download PDF

Info

Publication number
CN114085900B
CN114085900B CN202111382255.5A CN202111382255A CN114085900B CN 114085900 B CN114085900 B CN 114085900B CN 202111382255 A CN202111382255 A CN 202111382255A CN 114085900 B CN114085900 B CN 114085900B
Authority
CN
China
Prior art keywords
thr
gly
val
ser
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111382255.5A
Other languages
English (en)
Other versions
CN114085900A (zh
Inventor
刘哲
梁庆渊
赵娜娜
赖开生
刘昕超
高璇
李方玉
侯青
惠汝太
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bosinor Beijing Medical Laboratory Co ltd
Original Assignee
Bosinor Beijing Medical Laboratory Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bosinor Beijing Medical Laboratory Co ltd filed Critical Bosinor Beijing Medical Laboratory Co ltd
Priority to CN202111382255.5A priority Critical patent/CN114085900B/zh
Publication of CN114085900A publication Critical patent/CN114085900A/zh
Application granted granted Critical
Publication of CN114085900B publication Critical patent/CN114085900B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明涉及人类遗传学和内科心血管技术领域,具体涉及了与遗传性肾小球疾病相关的突变基因,与野生型FN1基因编码DNA的参考序列相比,突变基因的核苷酸序列为SEQ ID NO:3;在基因组位置chr2:216273077处,碱基A突变为碱基G;参考基因组版本是GRCh37。本发明还涉及上述与遗传性肾小球疾病相关的突变基因在制备检测试剂盒中的应用。本发明提供的突变基因可以作为临床辅助诊断的生物标志物;检测该变异的携带者,为受试者提供优生优育指导和遗传咨询,减少患儿出生,对纤维连接蛋白肾小球病的早期诊断,或者辅助临床判断具有重要意义。

Description

与遗传性肾小球疾病相关的突变基因及其应用
技术领域
本发明涉及人类遗传学和内科心血管技术领域,尤其涉及与遗传性肾小球疾病相关的突变基因及其应用。
背景技术
纤维连接蛋白肾小球病(fibronectin glomerulopathy,FNG)于1987年由Tuttle等首先报道是一种具有家族遗传性的常染色体显性遗传性肾小球疾病,主要临床表现为:肾性高血压,蛋白尿,镜下血尿,肾病综合征,肾功能衰竭,终末期肾病,肾小球扩张,系膜和内皮下颗粒状或纤维性沉积物,发病年龄3~65岁,年轻人多见,男女均可受累,文献报道84%的患者首发症状在50岁之前,老年发病者多为女性。目前尚无特异性治疗,一般多给予对症治疗。Castelletti等报告40%FNG患者携带突变基因FN1。
FN1基因编码纤维连接蛋白,在细胞表面和细胞外基质中以二聚体或多聚体形式存在。纤维连接蛋白参与细胞粘附和迁移过程,包括胚胎形成,伤口愈合,凝血,宿主防御和转移。
目前已发现大量FN1基因突变位点,例如c.3452C>T、c.2674T>A、c.2638T>C等等,但是仍存在未知的FN1基因突变位点,进一步发现新的FN1基因的突变位点对于研究纤维连接蛋白肾小球病的发病机制,对纤维连接蛋白肾小球病的早期诊断,或者辅助临床判断具有重要意义。
发明内容
本发明的目的是针对纤维连接蛋白肾小球病,提供一种与遗传性肾小球疾病相关的突变基因及其应用。
本发明提供的技术方案如下:
一、本发明提供与遗传性肾小球疾病相关的突变基因,与野生型FN1基因编码DNA的参考序列相比,突变基因的核苷酸序列为SEQ ID NO:3;在基因组位置chr2:216273077处,碱基A突变为碱基G;参考基因组版本是GRCh37。
二、本发明还提供了上述与遗传性肾小球疾病相关的突变基因在制备检测试剂盒中的应用。
优选地,所述纤维连接蛋白肾小球病检测试剂盒包括引物SEQ ID NO:1和SEQ IDNO:2。
优选地,所述纤维连接蛋白肾小球病检测试剂盒还包括Taq DNA聚合酶和PCR缓冲液。
三、本发明的原理和有益效果在于:
本发明公开的突变基因可以作为临床辅助诊断的生物标志物,对纤维连接蛋白肾小球病的早期诊断,或者辅助临床判断具有重要意义;基于与遗传性肾小球疾病相关的突变基因开发的检测试剂盒,可以检测出具有纤维连接蛋白肾小球病突变基因的患者,为受试者提供优生优育指导和遗传咨询,减少患儿出生。
附图说明
图1为实施例3的家系图;
图2为实施例3中先证者、先证者母亲等人的Sanger测序图;
图3为实施例3家系中先证者父亲、先证者妹妹等人的Sanger测序图。
具体实施方式
下面通过具体实施方式进一步详细说明:
实施例1-与遗传性肾小球疾病相关的突变基因
与遗传性肾小球疾病相关的突变基因,具体突变如下表1所示:
表1与遗传性肾小球疾病相关的突变基因的具体检测结果
基因 基因组位置 转录本号 碱基改变 氨基酸改变 参考基因组版本 外显子号
FN1 chr2:216273077 NM_001306129 c.2372A>G p.Tyr791Cys GRCh37/hg19 Exon16
(1)在基因组位置chr2:216273076-chr2:216273125处,野生型FN1基因的序列为:
TGAACATCCCTGACCTGCTTCCTGGCCGAAAATACATTGTAAATGTCT
Figure BDA0003366025210000021
T,
Figure BDA0003366025210000022
为野生型FN1基因在基因组chr2:216273077处的碱基。
在对应基因组位置处,与遗传性肾小球疾病相关的突变基因的序列为:
TGAACATCCCTGACCTGCTTCCTGGCCGAAAATACATTGTAAATGTCT
Figure BDA0003366025210000023
T,
Figure BDA0003366025210000024
为突变基因FN1在基因组chr2:216273077处的碱基。
(2)转录本号为NM_001306129时,野生型FN1基因编码DNA的参考序列为:
ATGCTTAGGGGTCCGGGGCCCGGGCTGCTGCTGCTGGCCGTCCAGTGCCTGGGGACAGCGGTGCCCTCCACGGGAGCCTCGAAGAGCAAGAGGCAGGCTCAGCAAATGGTTCAGCCCCAGTCCCCGGTGGCTGTCAGTCAAAGCAAGCCCGGTTGTTATGACAATGGAAAACACTATCAGATAAATCAACAGTGGGAGCGGACCTACCTAGGCAATGCGTTGGTTTGTACTTGTTATGGAGGAAGCCGAGGTTTTAACTGCGAGAGTAAACCTGAAGCTGAAGAGACTTGCTTTGACAAGTACACTGGGAACACTTACCGAGTGGGTGACACTTATGAGCGTCCTAAAGACTCCATGATCTGGGACTGTACCTGCATCGGGGCTGGGCGAGGGAGAATAAGCTGTACCATCGCAAACCGCTGCCATGAAGGGGGTCAGTCCTACAAGATTGGTGACACCTGGAGGAGACCACATGAGACTGGTGGTTACATGTTAGAGTGTGTGTGTCTTGGTAATGGAAAAGGAGAATGGACCTGCAAGCCCATAGCTGAGAAGTGTTTTGATCATGCTGCTGGGACTTCCTATGTGGTCGGAGAAACGTGGGAGAAGCCCTACCAAGGCTGGATGATGGTAGATTGTACTTGCCTGGGAGAAGGCAGCGGACGCATCACTTGCACTTCTAGAAATAGATGCAACGATCAGGACACAAGGACATCCTATAGAATTGGAGACACCTGGAGCAAGAAGGATAATCGAGGAAACCTGCTCCAGTGCATCTGCACAGGCAACGGCCGAGGAGAGTGGAAGTGTGAGAGGCACACCTCTGTGCAGACCACATCGAGCGGATCTGGCCCCTTCACCGATGTTCGTGCAGCTGTTTACCAACCGCAGCCTCACCCCCAGCCTCCTCCCTATGGCCACTGTGTCACAGACAGTGGTGTGGTCTACTCTGTGGGGATGCAGTGGCTGAAGACACAAGGAAATAAGCAAATGCTTTGCACGTGCCTGGGCAACGGAGTCAGCTGCCAAGAGACAGCTGTAACCCAGACTTACGGTGGCAACTCAAATGGAGAGCCATGTGTCTTACCATTCACCTACAATGGCAGGACGTTCTACTCCTGCACCACAGAAGGGCGACAGGACGGACATCTTTGGTGCAGCACAACTTCGAATTATGAGCAGGACCAGAAATACTCTTTCTGCACAGACCACACTGTTTTGGTTCAGACTCGAGGAGGAAATTCCAATGGTGCCTTGTGCCACTTCCCCTTCCTATACAACAACCACAATTACACTGATTGCACTTCTGAGGGCAGAAGAGACAACATGAAGTGGTGTGGGACCACACAGAACTATGATGCCGACCAGAAGTTTGGGTTCTGCCCCATGGCTGCCCACGAGGAAATCTGCACAACCAATGAAGGGGTCATGTACCGCATTGGAGATCAGTGGGATAAGCAGCATGACATGGGTCACATGATGAGGTGCACGTGTGTTGGGAATGGTCGTGGGGAATGGACATGCATTGCCTACTCGCAGCTTCGAGATCAGTGCATTGTTGATGACATCACTTACAATGTGAACGACACATTCCACAAGCGTCATGAAGAGGGGCACATGCTGAACTGTACATGCTTCGGTCAGGGTCGGGGCAGGTGGAAGTGTGATCCCGTCGACCAATGCCAGGATTCAGAGACTGGGACGTTTTATCAAATTGGAGATTCATGGGAGAAGTATGTGCATGGTGTCAGATACCAGTGCTACTGCTATGGCCGTGGCATTGGGGAGTGGCATTGCCAACCTTTACAGACCTATCCAAGCTCAAGTGGTCCTGTCGAAGTATTTATCACTGAGACTCCGAGTCAGCCCAACTCCCACCCCATCCAGTGGAATGCACCACAGCCATCTCACATTTCCAAGTACATTCTCAGGTGGAGACCTAAAAATTCTGTAGGCCGTTGGAAGGAAGCTACCATACCAGGCCACTTAAACTCCTACACCATCAAAGGCCTGAAGCCTGGTGTGGTATACGAGGGCCAGCTCATCAGCATCCAGCAGTACGGCCACCAAGAAGTGACTCGCTTTGACTTCACCACCACCAGCACCAGCACACCTGTGACCAGCAACACCGTGACAGGAGAGACGACTCCCTTTTCTCCTCTTGTGGCCACTTCTGAATCTGTGACCGAAATCACAGCCAGTAGCTTTGTGGTCTCCTGGGTCTCAGCTTCCGACACCGTGTCGGGATTCCGGGTGGAATATGAGCTGAGTGAGGAGGGAGATGAGCCACAGTACCTGGATCTTCCAAGCACAGCCACTTCTGTGAACATCCCTGACCTGCTTCCTGGCCGAAAATACATTGTAAATGTCT
Figure BDA0003366025210000031
TCAGATATCTGAGGATGGGGAGCAGAGTTTGATCCTGTCTACTTCACAAACAACAGCGCCTGATGCCCCTCCTGACACGACTGTGGACCAAGTTGATGACACCTCAATTGTTGTTCGCTGGAGCAGACCCCAGGCTCCCATCACAGGGTACAGAATAGTCTATTCGCCATCAGTAGAAGGTAGCAGCACAGAACTCAACCTTCCTGAAACTGCAAACTCCGTCACCCTCAGTGACTTGCAACCTGGTGTTCAGTATAACATCACTATCTATGCTGTGGAAGAAAATCAAGAAAGTACACCTGTTGTCATTCAACAAGAAACCACTGGCACCCCACGCTCAGATACAGTGCCCTCTCCCAGGGACCTGCAGTTTGTGGAAGTGACAGACGTGAAGGTCACCATCATGTGGACACCGCCTGAGAGTGCAGTGACCGGCTACCGTGTGGATGTGATCCCCGTCAACCTGCCTGGCGAGCACGGGCAGAGGCTGCCCATCAGCAGGAACACCTTTGCAGAAGTCACCGGGCTGTCCCCTGGGGTCACCTATTACTTCAAAGTCTTTGCAGTGAGCCATGGGAGGGAGAGCAAGCCTCTGACTGCTCAACAGACAACCAAACTGGATGCTCCCACTAACCTCCAGTTTGTCAATGAAACTGATTCTACTGTCCTGGTGAGATGGACTCCACCTCGGGCCCAGATAACAGGATACCGACTGACCGTGGGCCTTACCCGAAGAGGACAGCCCAGGCAGTACAATGTGGGTCCCTCTGTCTCCAAGTACCCACTGAGGAATCTGCAGCCTGCATCTGAGTACACCGTATCCCTCGTGGCCATAAAGGGCAACCAAGAGAGCCCCAAAGCCACTGGAGTCTTTACCACACTGCAGCCTGGGAGCTCTATTCCACCTTACAACACCGAGGTGACTGAGACCACCATTGTGATCACATGGACGCCTGCTCCAAGAATTGGTTTTAAGCTGGGTGTACGACCAAGCCAGGGAGGAGAGGCACCACGAGAAGTGACTTCAGACTCAGGAAGCATCGTTGTGTCCGGCTTGACTCCAGGAGTAGAATACGTCTACACCATCCAAGTCCTGAGAGATGGACAGGAAAGAGATGCGCCAATTGTAAACAAAGTGGTGACACCATTGTCTCCACCAACAAACTTGCATCTGGAGGCAAACCCTGACACTGGAGTGCTCACAGTCTCCTGGGAGAGGAGCACCACCCCAGACATTACTGGTTATAGAATTACCACAACCCCTACAAACGGCCAGCAGGGAAATTCTTTGGAAGAAGTGGTCCATGCTGATCAGAGCTCCTGCACTTTTGATAACCTGAGTCCCGGCCTGGAGTACAATGTCAGTGTTTACACTGTCAAGGATGACAAGGAAAGTGTCCCTATCTCTGATACCATCATCCCAGAGGTGCCCCAACTCACTGACCTAAGCTTTGTTGATATAACCGATTCAAGCATCGGCCTGAGGTGGACCCCGCTAAACTCTTCCACCATTATTGGGTACCGCATCACAGTAGTTGCGGCAGGAGAAGGTATCCCTATTTTTGAAGATTTTGTGGACTCCTCAGTAGGATACTACACAGTCACAGGGCTGGAGCCGGGCATTGACTATGATATCAGCGTTATCACTCTCATTAATGGCGGCGAGAGTGCCCCTACTACACTGACACAACAAACGGCTGTTCCTCCTCCCACTGACCTGCGATTCACCAACATTGGTCCAGACACCATGCGTGTCACCTGGGCTCCACCCCCATCCATTGATTTAACCAACTTCCTGGTGCGTTACTCACCTGTGAAAAATGAGGAAGATGTTGCAGAGTTGTCAATTTCTCCTTCAGACAATGCAGTGGTCTTAACAAATCTCCTGCCTGGTACAGAATATGTAGTGAGTGTCTCCAGTGTCTACGAACAACATGAGAGCACACCTCTTAGAGGAAGACAGAAAACAGGTCTTGATTCCCCAACTGGCATTGACTTTTCTGATATTACTGCCAACTCTTTTACTGTGCACTGGATTGCTCCTCGAGCCACCATCACTGGCTACAGGATCCGCCATCATCCCGAGCACTTCAGTGGGAGACCTCGAGAAGATCGGGTGCCCCACTCTCGGAATTCCATCACCCTCACCAACCTCACTCCAGGCACAGAGTATGTGGTCAGCATCGTTGCTCTTAATGGCAGAGAGGAAAGTCCCTTATTGATTGGCCAACAATCAACAGTTTCTGATGTTCCGAGGGACCTGGAAGTTGTTGCTGCGACCCCCACCAGCCTACTGATCAGCTGGGATGCTCCTGCTGTCACAGTGAGATATTACAGGATCACTTACGGAGAGACAGGAGGAAATAGCCCTGTCCAGGAGTTCACTGTGCCTGGGAGCAAGTCTACAGCTACCATCAGCGGCCTTAAACCTGGAGTTGATTATACCATCACTGTGTATGCTGTCACTGGCCGTGGAGACAGCCCCGCAAGCAGCAAGCCAATTTCCATTAATTACCGAACAGAAATTGACAAACCATCCCAGATGCAAGTGACCGATGTTCAGGACAACAGCATTAGTGTCAAGTGGCTGCCTTCAAGTTCCCCTGTTACTGGTTACAGAGTAACCACCACTCCCAAAAATGGACCAGGACCAACAAAAACTAAAACTGCAGGTCCAGATCAAACAGAAATGACTATTGAAGGCTTGCAGCCCACAGTGGAGTATGTGGTTAGTGTCTATGCTCAGAATCCAAGCGGAGAGAGTCAGCCTCTGGTTCAGACTGCAGTAACCAACATTGATCGCCCTAAAGGACTGGCATTCACTGATGTGGATGTCGATTCCATCAAAATTGCTTGGGAAAGCCCACAGGGGCAAGTTTCCAGGTACAGGGTGACCTACTCGAGCCCTGAGGATGGAATCCATGAGCTATTCCCTGCACCTGATGGTGAAGAAGACACTGCAGAGCTGCAAGGCCTCAGACCGGGTTCTGAGTACACAGTCAGTGTGGTTGCCTTGCACGATGATATGGAGAGCCAGCCCCTGATTGGAACCCAGTCCACAGCTATTCCTGCACCAACTGACCTGAAGTTCACTCAGGTCACACCCACAAGCCTGAGCGCCCAGTGGACACCACCCAATGTTCAGCTCACTGGATATCGAGTGCGGGTGACCCCCAAGGAGAAGACCGGACCAATGAAAGAAATCAACCTTGCTCCTGACAGCTCATCCGTGGTTGTATCAGGACTTATGGTGGCCACCAAATATGAAGTGAGTGTCTATGCTCTTAAGGACACTTTGACAAGCAGACCAGCTCAGGGAGTTGTCACCACTCTGGAGAATGTCAGCCCACCAAGAAGGGCTCGTGTGACAGATGCTACTGAGACCACCATCACCATTAGCTGGAGAACCAAGACTGAGACGATCACTGGCTTCCAAGTTGATGCCGTTCCAGCCAATGGCCAGACTCCAATCCAGAGAACCATCAAGCCAGATGTCAGAAGCTACACCATCACAGGTTTACAACCAGGCACTGACTACAAGATCTACCTGTACACCTTGAATGACAATGCTCGGAGCTCCCCTGTGGTCATCGACGCCTCCACTGCCATTGATGCACCATCCAACCTGCGTTTCCTGGCCACCACACCCAATTCCTTGCTGGTATCATGGCAGCCGCCACGTGCCAGGATTACCGGCTACATCATCAAGTATGAGAAGCCTGGGTCTCCTCCCAGAGAAGTGGTCCCTCGGCCCCGCCCTGGTGTCACAGAGGCTACTATTACTGGCCTGGAACCGGGAACCGAATATACAATTTATGTCATTGCCCTGAAGAATAATCAGAAGAGCGAGCCCCTGATTGGAAGGAAAAAGACAGACGAGCTTCCCCAACTGGTAACCCTTCCACACCCCAATCTTCATGGACCAGAGATCTTGGATGTTCCTTCCACAGTTCAAAAGACCCCTTTCGTCACCCACCCTGGGTATGACACTGGAAATGGTATTCAGCTTCCTGGCACTTCTGGTCAGCAACCCAGTGTTGGGCAACAAATGATCTTTGAGGAACATGGTTTTAGGCGGACCACACCGCCCACAACGGCCACCCCCATAAGGCATAGGCCAAGACCATACCCGCCGAATGTAGGACAAGAAGCTCTCTCTCAGACAACCATCTCATGGGCCCCATTCCAGGACACTTCTGAGTACATCATTTCATGTCATCCTGTTGGCACTGATGAAGAACCCTTACAGTTCAGGGTTCCTGGAACTTCTACCAGTGCCACTCTGACAGGCCTCACCAGAGGTGCCACCTACAACGTCATAGTGGAGGCACTGAAAGACCAGCAGAGGCATAAGGTTCGGGAAGAGGTTGTTACCGTGGGCAACTCTGTCAACGAAGGCTTGAACCAACCTACGGATGACTCGTGCTTTGACCCCTACACAGTTTCCCATTATGCCGTTGGAGATGAGTGGGAACGAATGTCTGAATCAGGCTTTAAACTGTTGTGCCAGTGCTTAGGCTTTGGAAGTGGTCATTTCAGATGTGATTCATCTAGATGGTGCCATGACAATGGTGTGAACTACAAGATTGGAGAGAAGTGGGACCGTCAGGGAGAAAATGGCCAGATGATGAGCTGCACATGTCTTGGGAACGGAAAAGGAGAATTCAAGTGTGACCCTCATGAGGCAACGTGTTATGATGATGGGAAGACATACCACGTAGGAGAACAGTGGCAGAAGGAATATCTCGGTGCCATTTGCTCCTGCACATGCTTTGGAGGCCAGCGGGGCTGGCGCTGTGACAACTGCCGCAGACCTGGGGGTGAACCCAGTCCCGAAGGCACTACTGGCCAGTCCTACAACCAGTATTCTCAGAGATACCATCAGAGAACAAACACTAATGTTAATTGCCCAATTGAGTGCTTCATGCCTTTAGATGTACAGGCTGACAGAGAAGATTCCCGAGAGTAA,
Figure BDA0003366025210000061
为野生型FN1基因编码DNA参考序列的第2372位突变前碱基。
c.2372A>G表示:与野生型FN1基因编码DNA的参考序列相比,突变基因FN1的第2372位点的碱基A突变为碱基G,具体编码DNA的核苷酸序列为SEQ ID NO:3。
(4)转录本号为NM_001306129时,野生型FN1基因编码蛋白为:
MLRGPGPGLLLLAVQCLGTAVPSTGASKSKRQAQQMVQPQSPVAVSQSKPGCYDNGKHYQINQQWERTYLGNALVCTCYGGSRGFNCESKPEAEETCFDKYTGNTYRVGDTYERPKDSMIWDCTCIGAGRGRISCTIANRCHEGGQSYKIGDTWRRPHETGGYMLECVCLGNGKGEWTCKPIAEKCFDHAAGTSYVVGETWEKPYQGWMMVDCTCLGEGSGRITCTSRNRCNDQDTRTSYRIGDTWSKKDNRGNLLQCICTGNGRGEWKCERHTSVQTTSSGSGPFTDVRAAVYQPQPHPQPPPYGHCVTDSGVVYSVGMQWLKTQGNKQMLCTCLGNGVSCQETAVTQTYGGNSNGEPCVLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHTVLVQTRGGNSNGALCHFPFLYNNHNYTDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTTNEGVMYRIGDQWDKQHDMGHMMRCTCVGNGRGEWTCIAYSQLRDQCIVDDITYNVNDTFHKRHEEGHMLNCTCFGQGRGRWKCDPVDQCQDSETGTFYQIGDSWEKYVHGVRYQCYCYGRGIGEWHCQPLQTYPSSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTPVTSNTVTGETTPFSPLVATSESVTEITASSFVVSWVSASDTVSGFRVEYELSEEGDEPQYLDLPSTATSVNIPDLLPGRKYIVNV
Figure BDA0003366025210000062
QISEDGEQSLILSTSQTTAPDAPPDTTVDQVDDTSIVVRWSRPQAPITGYRIVYSPSVEGSSTELNLPETANSVTLSDLQPGVQYNITIYAVEENQESTPVVIQQETTGTPRSDTVPSPRDLQFVEVTDVKVTIMWTPPESAVTGYRVDVIPVNLPGEHGQRLPISRNTFAEVTGLSPGVTYYFKVFAVSHGRESKPLTAQQTTKLDAPTNLQFVNETDSTVLVRWTPPRAQITGYRLTVGLTRRGQPRQYNVGPSVSKYPLRNLQPASEYTVSLVAIKGNQESPKATGVFTTLQPGSSIPPYNTEVTETTIVITWTPAPRIGFKLGVRPSQGGEAPREVTSDSGSIVVSGLTPGVEYVYTIQVLRDGQERDAPIVNKVVTPLSPPTNLHLEANPDTGVLTVSWERSTTPDITGYRITTTPTNGQQGNSLEEVVHADQSSCTFDNLSPGLEYNVSVYTVKDDKESVPISDTIIPEVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSVGYYTVTGLEPGIDYDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKNEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTGLDSPTGIDFSDITANSFTVHWIAPRATITGYRIRHHPEHFSGRPREDRVPHSRNSITLTNLTPGTEYVVSIVALNGREESPLLIGQQSTVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKTKTAGPDQTEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTNIDRPKGLAFTDVDVDSIKIAWESPQGQVSRYRVTYSSPEDGIHELFPAPDGEEDTAELQGLRPGSEYTVSVVALHDDMESQPLIGTQSTAIPAPTDLKFTQVTPTSLSAQWTPPNVQLTGYRVRVTPKEKTGPMKEINLAPDSSSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVSPPRRARVTDATETTITISWRTKTETITGFQVDAVPANGQTPIQRTIKPDVRSYTITGLQPGTDYKIYLYTLNDNARSSPVVIDASTAIDAPSNLRFLATTPNSLLVSWQPPRARITGYIIKYEKPGSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTDELPQLVTLPHPNLHGPEILDVPSTVQKTPFVTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFRRTTPPTTATPIRHRPRPYPPNVGQEALSQTTISWAPFQDTSEYIISCHPVGTDEEPLQFRVPGTSTSATLTGLTRGATYNVIVEALKDQQRHKVREEVVTVGNSVNEGLNQPTDDSCFDPYTVSHYAVGDEWERMSESGFKLLCQCLGFGSGHFRCDSSRWCHDNGVNYKIGEKWDRQGENGQMMSCTCLGNGKGEFKCDPHEATCYDDGKTYHVGEQWQKEYLGAICSCTCFGGQRGWRCDNCRRPGGEPSPEGTTGQSYNQYSQRYHQRTNTNVNCPIECFMPLDVQADREDSRE。
Figure BDA0003366025210000071
为野生型FN1基因编码蛋白的第791位酪氨酸(Tyr,Y)。
p.Tyr791Cys表示:与野生型FN1基因编码蛋白的氨基酸序列相比,突变基因FN1编码蛋白的氨基酸第791位的酪氨酸(Tyr,Y)突变为半胱氨酸(Cys,C),具体氨基酸序列为SEQID NO:4。
(5)查询人群频率数据库发现FN1基因c.2372A>G杂合错义变异(FN1:p.Tyr791Cyshet)为罕见变异(千人基因组:无,ESP6500:无,ExAC:无)。
采用多个生物信息预测软件(包括SIFT和Polyphen-2等)交叉预测,结果多为有害(SIFT为“D”,Polyphen-2为“D”,MutationTaster_pred为“D”,VEST3评分为“0.882”,其他为“3个T/2个D/1个M”),氨基酸由极性不带电荷的酪氨酸变为极性不带电荷的半胱氨酸,提示该变异所致的氨基酸改变可能会对蛋白功能产生影响。查询数据库发现该位置的氨基酸在脊椎动物中保守性好。查询ClinVar、HGMD数据库未发现该变异,文献检索未发现该变异与疾病相关的报导。根据现有证据:该变异为罕见变异、软件预测该变异可能会对蛋白功能产生影响、该位置氨基酸在脊椎动物中保守性好,但缺乏家系连锁及功能学证据支持,所以该变异为可疑致病变异(C1级)。
实施例2-与遗传性肾小球疾病相关的突变基因的检测试剂盒
与遗传性肾小球疾病相关的突变基因的检测试剂盒,包括Taq DNA聚合酶、PCR缓冲液和引物等。具体引物如下:
上游引物(FN1-E16F,SEQ ID NO:1):5'AGCACATTACCTTCTAGTCGCTT 3”;
下游引物(FN1-E16R,SEQ ID NO:2):5'AACTTGGTCCACAGTCGTGTC 3';
长度:394bp。
利用本试剂盒筛选突变的致病基因FN1的具体步骤为:提取待测者DNA,然后使用经设计的引物组合(SEQ ID NO:1和SEQ ID NO:2)对FN1基因进行扩增,得到PCR产物,使用1.5%的琼脂糖凝胶电泳检测PCR产物,选用1000bp Marker作为参考,检测验证扩增产物为预期的大小,最后对PCR产物进行测序。从NCBI(https://www.ncbi.nlm.nih.gov/)数据库获得参考序列和测序结果进行比对,判断待测者FN1基因是否携带c.2372A>G杂合错义变异,协助临床确诊纤维连接蛋白肾小球病。
实施例3-家系验证实验
本实施例采用家系连锁分析方法验证与遗传性肾小球疾病相关的突变基因的致病性。
具体地,选取一个家族性纤维连接蛋白肾小球病家系中的三代成员,该家系中的先证者(女,15岁)临床被诊断为纤维连接蛋白肾小球病。
在先证者及其家属自愿签署知情同意书的前提下,寄送5-10mL全血样本,建立病历资料库,详细记录先证者病情、家系情况等资料。本研究已得到本单位伦理委员会批准。
先证者临床概况描述:
表3先证者临床概况
Figure BDA0003366025210000081
Figure BDA0003366025210000091
采用实施例2提供的检测试剂盒对先证者及其家属的FN1基因进行基因检测,结果如图1-图3所示,图1为实施例3的家系图;图2为实施例3中先证者、先证者母亲等人的Sanger测序图;图3为实施例3家系中先证者父亲、先证者妹妹等人的Sanger测序图。
如图1-图3所示,家系中临床诊断出纤维连接蛋白肾小球病的先证者、先证者母亲等人均携带了突变的FN1基因,而未患有纤维连接蛋白肾小球病的家系成员均未携带突变的FN1基因,由此验证可以说明突变的FN1基因对纤维连接蛋白肾小球病的致病性。
实施例4-针对家系外正常人的验证实验
采用实施例2的检测试剂盒,对700例家系外正常人进行FN1基因检测,结果均未能检测到该突变。
实施例5-针对家系外家族遗传性纤维连接蛋白肾小球病患者的验证实验
在中国范围内,对患有纤维连接蛋白肾小球病、肥厚型心肌病、扩张型心肌病、长QT等单基因遗传病的患者中检测FN1基因,患者总共1900例,每种疾病的患病人数不等,结果显示,除实施例3提供的家系外,仅在临床诊断患有纤维连接蛋白肾小球病的2例患者中检测到具有c.2372A>G杂合错义变异的突变基因FN1。
本实验再次验证说明突变的FN1致病基因的会导致纤维连接蛋白肾小球病,支持临床诊断。
以上详细描述了本发明的较佳具体实施例。应当理解,本领域的普通技术人员无需创造性劳动就可以根据本发明的构思作出诸多修改和变化。因此,凡本技术领域中技术人员依本发明的构思在现有技术的基础上通过逻辑分析、推理或者有限的实验可以得到的技术方案,皆应在由权利要求书所确定的保护范围内。
序列表
<110> 百世诺(北京)医学检验实验室有限公司
<120> 与遗传性肾小球疾病相关的突变基因及其应用
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> homo sapiens
<400> 1
agcacattac cttctagtcg ctt 23
<210> 2
<211> 21
<212> DNA
<213> homo sapiens
<400> 2
aacttggtcc acagtcgtgt c 21
<210> 3
<211> 7341
<212> DNA
<213> homo sapiens
<400> 3
atgcttaggg gtccggggcc cgggctgctg ctgctggccg tccagtgcct ggggacagcg 60
gtgccctcca cgggagcctc gaagagcaag aggcaggctc agcaaatggt tcagccccag 120
tccccggtgg ctgtcagtca aagcaagccc ggttgttatg acaatggaaa acactatcag 180
ataaatcaac agtgggagcg gacctaccta ggcaatgcgt tggtttgtac ttgttatgga 240
ggaagccgag gttttaactg cgagagtaaa cctgaagctg aagagacttg ctttgacaag 300
tacactggga acacttaccg agtgggtgac acttatgagc gtcctaaaga ctccatgatc 360
tgggactgta cctgcatcgg ggctgggcga gggagaataa gctgtaccat cgcaaaccgc 420
tgccatgaag ggggtcagtc ctacaagatt ggtgacacct ggaggagacc acatgagact 480
ggtggttaca tgttagagtg tgtgtgtctt ggtaatggaa aaggagaatg gacctgcaag 540
cccatagctg agaagtgttt tgatcatgct gctgggactt cctatgtggt cggagaaacg 600
tgggagaagc cctaccaagg ctggatgatg gtagattgta cttgcctggg agaaggcagc 660
ggacgcatca cttgcacttc tagaaataga tgcaacgatc aggacacaag gacatcctat 720
agaattggag acacctggag caagaaggat aatcgaggaa acctgctcca gtgcatctgc 780
acaggcaacg gccgaggaga gtggaagtgt gagaggcaca cctctgtgca gaccacatcg 840
agcggatctg gccccttcac cgatgttcgt gcagctgttt accaaccgca gcctcacccc 900
cagcctcctc cctatggcca ctgtgtcaca gacagtggtg tggtctactc tgtggggatg 960
cagtggctga agacacaagg aaataagcaa atgctttgca cgtgcctggg caacggagtc 1020
agctgccaag agacagctgt aacccagact tacggtggca actcaaatgg agagccatgt 1080
gtcttaccat tcacctacaa tggcaggacg ttctactcct gcaccacaga agggcgacag 1140
gacggacatc tttggtgcag cacaacttcg aattatgagc aggaccagaa atactctttc 1200
tgcacagacc acactgtttt ggttcagact cgaggaggaa attccaatgg tgccttgtgc 1260
cacttcccct tcctatacaa caaccacaat tacactgatt gcacttctga gggcagaaga 1320
gacaacatga agtggtgtgg gaccacacag aactatgatg ccgaccagaa gtttgggttc 1380
tgccccatgg ctgcccacga ggaaatctgc acaaccaatg aaggggtcat gtaccgcatt 1440
ggagatcagt gggataagca gcatgacatg ggtcacatga tgaggtgcac gtgtgttggg 1500
aatggtcgtg gggaatggac atgcattgcc tactcgcagc ttcgagatca gtgcattgtt 1560
gatgacatca cttacaatgt gaacgacaca ttccacaagc gtcatgaaga ggggcacatg 1620
ctgaactgta catgcttcgg tcagggtcgg ggcaggtgga agtgtgatcc cgtcgaccaa 1680
tgccaggatt cagagactgg gacgttttat caaattggag attcatggga gaagtatgtg 1740
catggtgtca gataccagtg ctactgctat ggccgtggca ttggggagtg gcattgccaa 1800
cctttacaga cctatccaag ctcaagtggt cctgtcgaag tatttatcac tgagactccg 1860
agtcagccca actcccaccc catccagtgg aatgcaccac agccatctca catttccaag 1920
tacattctca ggtggagacc taaaaattct gtaggccgtt ggaaggaagc taccatacca 1980
ggccacttaa actcctacac catcaaaggc ctgaagcctg gtgtggtata cgagggccag 2040
ctcatcagca tccagcagta cggccaccaa gaagtgactc gctttgactt caccaccacc 2100
agcaccagca cacctgtgac cagcaacacc gtgacaggag agacgactcc cttttctcct 2160
cttgtggcca cttctgaatc tgtgaccgaa atcacagcca gtagctttgt ggtctcctgg 2220
gtctcagctt ccgacaccgt gtcgggattc cgggtggaat atgagctgag tgaggaggga 2280
gatgagccac agtacctgga tcttccaagc acagccactt ctgtgaacat ccctgacctg 2340
cttcctggcc gaaaatacat tgtaaatgtc tgtcagatat ctgaggatgg ggagcagagt 2400
ttgatcctgt ctacttcaca aacaacagcg cctgatgccc ctcctgacac gactgtggac 2460
caagttgatg acacctcaat tgttgttcgc tggagcagac cccaggctcc catcacaggg 2520
tacagaatag tctattcgcc atcagtagaa ggtagcagca cagaactcaa ccttcctgaa 2580
actgcaaact ccgtcaccct cagtgacttg caacctggtg ttcagtataa catcactatc 2640
tatgctgtgg aagaaaatca agaaagtaca cctgttgtca ttcaacaaga aaccactggc 2700
accccacgct cagatacagt gccctctccc agggacctgc agtttgtgga agtgacagac 2760
gtgaaggtca ccatcatgtg gacaccgcct gagagtgcag tgaccggcta ccgtgtggat 2820
gtgatccccg tcaacctgcc tggcgagcac gggcagaggc tgcccatcag caggaacacc 2880
tttgcagaag tcaccgggct gtcccctggg gtcacctatt acttcaaagt ctttgcagtg 2940
agccatggga gggagagcaa gcctctgact gctcaacaga caaccaaact ggatgctccc 3000
actaacctcc agtttgtcaa tgaaactgat tctactgtcc tggtgagatg gactccacct 3060
cgggcccaga taacaggata ccgactgacc gtgggcctta cccgaagagg acagcccagg 3120
cagtacaatg tgggtccctc tgtctccaag tacccactga ggaatctgca gcctgcatct 3180
gagtacaccg tatccctcgt ggccataaag ggcaaccaag agagccccaa agccactgga 3240
gtctttacca cactgcagcc tgggagctct attccacctt acaacaccga ggtgactgag 3300
accaccattg tgatcacatg gacgcctgct ccaagaattg gttttaagct gggtgtacga 3360
ccaagccagg gaggagaggc accacgagaa gtgacttcag actcaggaag catcgttgtg 3420
tccggcttga ctccaggagt agaatacgtc tacaccatcc aagtcctgag agatggacag 3480
gaaagagatg cgccaattgt aaacaaagtg gtgacaccat tgtctccacc aacaaacttg 3540
catctggagg caaaccctga cactggagtg ctcacagtct cctgggagag gagcaccacc 3600
ccagacatta ctggttatag aattaccaca acccctacaa acggccagca gggaaattct 3660
ttggaagaag tggtccatgc tgatcagagc tcctgcactt ttgataacct gagtcccggc 3720
ctggagtaca atgtcagtgt ttacactgtc aaggatgaca aggaaagtgt ccctatctct 3780
gataccatca tcccagaggt gccccaactc actgacctaa gctttgttga tataaccgat 3840
tcaagcatcg gcctgaggtg gaccccgcta aactcttcca ccattattgg gtaccgcatc 3900
acagtagttg cggcaggaga aggtatccct atttttgaag attttgtgga ctcctcagta 3960
ggatactaca cagtcacagg gctggagccg ggcattgact atgatatcag cgttatcact 4020
ctcattaatg gcggcgagag tgcccctact acactgacac aacaaacggc tgttcctcct 4080
cccactgacc tgcgattcac caacattggt ccagacacca tgcgtgtcac ctgggctcca 4140
cccccatcca ttgatttaac caacttcctg gtgcgttact cacctgtgaa aaatgaggaa 4200
gatgttgcag agttgtcaat ttctccttca gacaatgcag tggtcttaac aaatctcctg 4260
cctggtacag aatatgtagt gagtgtctcc agtgtctacg aacaacatga gagcacacct 4320
cttagaggaa gacagaaaac aggtcttgat tccccaactg gcattgactt ttctgatatt 4380
actgccaact cttttactgt gcactggatt gctcctcgag ccaccatcac tggctacagg 4440
atccgccatc atcccgagca cttcagtggg agacctcgag aagatcgggt gccccactct 4500
cggaattcca tcaccctcac caacctcact ccaggcacag agtatgtggt cagcatcgtt 4560
gctcttaatg gcagagagga aagtccctta ttgattggcc aacaatcaac agtttctgat 4620
gttccgaggg acctggaagt tgttgctgcg acccccacca gcctactgat cagctgggat 4680
gctcctgctg tcacagtgag atattacagg atcacttacg gagagacagg aggaaatagc 4740
cctgtccagg agttcactgt gcctgggagc aagtctacag ctaccatcag cggccttaaa 4800
cctggagttg attataccat cactgtgtat gctgtcactg gccgtggaga cagccccgca 4860
agcagcaagc caatttccat taattaccga acagaaattg acaaaccatc ccagatgcaa 4920
gtgaccgatg ttcaggacaa cagcattagt gtcaagtggc tgccttcaag ttcccctgtt 4980
actggttaca gagtaaccac cactcccaaa aatggaccag gaccaacaaa aactaaaact 5040
gcaggtccag atcaaacaga aatgactatt gaaggcttgc agcccacagt ggagtatgtg 5100
gttagtgtct atgctcagaa tccaagcgga gagagtcagc ctctggttca gactgcagta 5160
accaacattg atcgccctaa aggactggca ttcactgatg tggatgtcga ttccatcaaa 5220
attgcttggg aaagcccaca ggggcaagtt tccaggtaca gggtgaccta ctcgagccct 5280
gaggatggaa tccatgagct attccctgca cctgatggtg aagaagacac tgcagagctg 5340
caaggcctca gaccgggttc tgagtacaca gtcagtgtgg ttgccttgca cgatgatatg 5400
gagagccagc ccctgattgg aacccagtcc acagctattc ctgcaccaac tgacctgaag 5460
ttcactcagg tcacacccac aagcctgagc gcccagtgga caccacccaa tgttcagctc 5520
actggatatc gagtgcgggt gacccccaag gagaagaccg gaccaatgaa agaaatcaac 5580
cttgctcctg acagctcatc cgtggttgta tcaggactta tggtggccac caaatatgaa 5640
gtgagtgtct atgctcttaa ggacactttg acaagcagac cagctcaggg agttgtcacc 5700
actctggaga atgtcagccc accaagaagg gctcgtgtga cagatgctac tgagaccacc 5760
atcaccatta gctggagaac caagactgag acgatcactg gcttccaagt tgatgccgtt 5820
ccagccaatg gccagactcc aatccagaga accatcaagc cagatgtcag aagctacacc 5880
atcacaggtt tacaaccagg cactgactac aagatctacc tgtacacctt gaatgacaat 5940
gctcggagct cccctgtggt catcgacgcc tccactgcca ttgatgcacc atccaacctg 6000
cgtttcctgg ccaccacacc caattccttg ctggtatcat ggcagccgcc acgtgccagg 6060
attaccggct acatcatcaa gtatgagaag cctgggtctc ctcccagaga agtggtccct 6120
cggccccgcc ctggtgtcac agaggctact attactggcc tggaaccggg aaccgaatat 6180
acaatttatg tcattgccct gaagaataat cagaagagcg agcccctgat tggaaggaaa 6240
aagacagacg agcttcccca actggtaacc cttccacacc ccaatcttca tggaccagag 6300
atcttggatg ttccttccac agttcaaaag acccctttcg tcacccaccc tgggtatgac 6360
actggaaatg gtattcagct tcctggcact tctggtcagc aacccagtgt tgggcaacaa 6420
atgatctttg aggaacatgg ttttaggcgg accacaccgc ccacaacggc cacccccata 6480
aggcataggc caagaccata cccgccgaat gtaggacaag aagctctctc tcagacaacc 6540
atctcatggg ccccattcca ggacacttct gagtacatca tttcatgtca tcctgttggc 6600
actgatgaag aacccttaca gttcagggtt cctggaactt ctaccagtgc cactctgaca 6660
ggcctcacca gaggtgccac ctacaacgtc atagtggagg cactgaaaga ccagcagagg 6720
cataaggttc gggaagaggt tgttaccgtg ggcaactctg tcaacgaagg cttgaaccaa 6780
cctacggatg actcgtgctt tgacccctac acagtttccc attatgccgt tggagatgag 6840
tgggaacgaa tgtctgaatc aggctttaaa ctgttgtgcc agtgcttagg ctttggaagt 6900
ggtcatttca gatgtgattc atctagatgg tgccatgaca atggtgtgaa ctacaagatt 6960
ggagagaagt gggaccgtca gggagaaaat ggccagatga tgagctgcac atgtcttggg 7020
aacggaaaag gagaattcaa gtgtgaccct catgaggcaa cgtgttatga tgatgggaag 7080
acataccacg taggagaaca gtggcagaag gaatatctcg gtgccatttg ctcctgcaca 7140
tgctttggag gccagcgggg ctggcgctgt gacaactgcc gcagacctgg gggtgaaccc 7200
agtcccgaag gcactactgg ccagtcctac aaccagtatt ctcagagata ccatcagaga 7260
acaaacacta atgttaattg cccaattgag tgcttcatgc ctttagatgt acaggctgac 7320
agagaagatt cccgagagta a 7341
<210> 4
<211> 2446
<212> PRT
<213> homo sapiens
<400> 4
Met Leu Arg Gly Pro Gly Pro Gly Leu Leu Leu Leu Ala Val Gln Cys
1 5 10 15
Leu Gly Thr Ala Val Pro Ser Thr Gly Ala Ser Lys Ser Lys Arg Gln
20 25 30
Ala Gln Gln Met Val Gln Pro Gln Ser Pro Val Ala Val Ser Gln Ser
35 40 45
Lys Pro Gly Cys Tyr Asp Asn Gly Lys His Tyr Gln Ile Asn Gln Gln
50 55 60
Trp Glu Arg Thr Tyr Leu Gly Asn Ala Leu Val Cys Thr Cys Tyr Gly
65 70 75 80
Gly Ser Arg Gly Phe Asn Cys Glu Ser Lys Pro Glu Ala Glu Glu Thr
85 90 95
Cys Phe Asp Lys Tyr Thr Gly Asn Thr Tyr Arg Val Gly Asp Thr Tyr
100 105 110
Glu Arg Pro Lys Asp Ser Met Ile Trp Asp Cys Thr Cys Ile Gly Ala
115 120 125
Gly Arg Gly Arg Ile Ser Cys Thr Ile Ala Asn Arg Cys His Glu Gly
130 135 140
Gly Gln Ser Tyr Lys Ile Gly Asp Thr Trp Arg Arg Pro His Glu Thr
145 150 155 160
Gly Gly Tyr Met Leu Glu Cys Val Cys Leu Gly Asn Gly Lys Gly Glu
165 170 175
Trp Thr Cys Lys Pro Ile Ala Glu Lys Cys Phe Asp His Ala Ala Gly
180 185 190
Thr Ser Tyr Val Val Gly Glu Thr Trp Glu Lys Pro Tyr Gln Gly Trp
195 200 205
Met Met Val Asp Cys Thr Cys Leu Gly Glu Gly Ser Gly Arg Ile Thr
210 215 220
Cys Thr Ser Arg Asn Arg Cys Asn Asp Gln Asp Thr Arg Thr Ser Tyr
225 230 235 240
Arg Ile Gly Asp Thr Trp Ser Lys Lys Asp Asn Arg Gly Asn Leu Leu
245 250 255
Gln Cys Ile Cys Thr Gly Asn Gly Arg Gly Glu Trp Lys Cys Glu Arg
260 265 270
His Thr Ser Val Gln Thr Thr Ser Ser Gly Ser Gly Pro Phe Thr Asp
275 280 285
Val Arg Ala Ala Val Tyr Gln Pro Gln Pro His Pro Gln Pro Pro Pro
290 295 300
Tyr Gly His Cys Val Thr Asp Ser Gly Val Val Tyr Ser Val Gly Met
305 310 315 320
Gln Trp Leu Lys Thr Gln Gly Asn Lys Gln Met Leu Cys Thr Cys Leu
325 330 335
Gly Asn Gly Val Ser Cys Gln Glu Thr Ala Val Thr Gln Thr Tyr Gly
340 345 350
Gly Asn Ser Asn Gly Glu Pro Cys Val Leu Pro Phe Thr Tyr Asn Gly
355 360 365
Arg Thr Phe Tyr Ser Cys Thr Thr Glu Gly Arg Gln Asp Gly His Leu
370 375 380
Trp Cys Ser Thr Thr Ser Asn Tyr Glu Gln Asp Gln Lys Tyr Ser Phe
385 390 395 400
Cys Thr Asp His Thr Val Leu Val Gln Thr Arg Gly Gly Asn Ser Asn
405 410 415
Gly Ala Leu Cys His Phe Pro Phe Leu Tyr Asn Asn His Asn Tyr Thr
420 425 430
Asp Cys Thr Ser Glu Gly Arg Arg Asp Asn Met Lys Trp Cys Gly Thr
435 440 445
Thr Gln Asn Tyr Asp Ala Asp Gln Lys Phe Gly Phe Cys Pro Met Ala
450 455 460
Ala His Glu Glu Ile Cys Thr Thr Asn Glu Gly Val Met Tyr Arg Ile
465 470 475 480
Gly Asp Gln Trp Asp Lys Gln His Asp Met Gly His Met Met Arg Cys
485 490 495
Thr Cys Val Gly Asn Gly Arg Gly Glu Trp Thr Cys Ile Ala Tyr Ser
500 505 510
Gln Leu Arg Asp Gln Cys Ile Val Asp Asp Ile Thr Tyr Asn Val Asn
515 520 525
Asp Thr Phe His Lys Arg His Glu Glu Gly His Met Leu Asn Cys Thr
530 535 540
Cys Phe Gly Gln Gly Arg Gly Arg Trp Lys Cys Asp Pro Val Asp Gln
545 550 555 560
Cys Gln Asp Ser Glu Thr Gly Thr Phe Tyr Gln Ile Gly Asp Ser Trp
565 570 575
Glu Lys Tyr Val His Gly Val Arg Tyr Gln Cys Tyr Cys Tyr Gly Arg
580 585 590
Gly Ile Gly Glu Trp His Cys Gln Pro Leu Gln Thr Tyr Pro Ser Ser
595 600 605
Ser Gly Pro Val Glu Val Phe Ile Thr Glu Thr Pro Ser Gln Pro Asn
610 615 620
Ser His Pro Ile Gln Trp Asn Ala Pro Gln Pro Ser His Ile Ser Lys
625 630 635 640
Tyr Ile Leu Arg Trp Arg Pro Lys Asn Ser Val Gly Arg Trp Lys Glu
645 650 655
Ala Thr Ile Pro Gly His Leu Asn Ser Tyr Thr Ile Lys Gly Leu Lys
660 665 670
Pro Gly Val Val Tyr Glu Gly Gln Leu Ile Ser Ile Gln Gln Tyr Gly
675 680 685
His Gln Glu Val Thr Arg Phe Asp Phe Thr Thr Thr Ser Thr Ser Thr
690 695 700
Pro Val Thr Ser Asn Thr Val Thr Gly Glu Thr Thr Pro Phe Ser Pro
705 710 715 720
Leu Val Ala Thr Ser Glu Ser Val Thr Glu Ile Thr Ala Ser Ser Phe
725 730 735
Val Val Ser Trp Val Ser Ala Ser Asp Thr Val Ser Gly Phe Arg Val
740 745 750
Glu Tyr Glu Leu Ser Glu Glu Gly Asp Glu Pro Gln Tyr Leu Asp Leu
755 760 765
Pro Ser Thr Ala Thr Ser Val Asn Ile Pro Asp Leu Leu Pro Gly Arg
770 775 780
Lys Tyr Ile Val Asn Val Cys Gln Ile Ser Glu Asp Gly Glu Gln Ser
785 790 795 800
Leu Ile Leu Ser Thr Ser Gln Thr Thr Ala Pro Asp Ala Pro Pro Asp
805 810 815
Thr Thr Val Asp Gln Val Asp Asp Thr Ser Ile Val Val Arg Trp Ser
820 825 830
Arg Pro Gln Ala Pro Ile Thr Gly Tyr Arg Ile Val Tyr Ser Pro Ser
835 840 845
Val Glu Gly Ser Ser Thr Glu Leu Asn Leu Pro Glu Thr Ala Asn Ser
850 855 860
Val Thr Leu Ser Asp Leu Gln Pro Gly Val Gln Tyr Asn Ile Thr Ile
865 870 875 880
Tyr Ala Val Glu Glu Asn Gln Glu Ser Thr Pro Val Val Ile Gln Gln
885 890 895
Glu Thr Thr Gly Thr Pro Arg Ser Asp Thr Val Pro Ser Pro Arg Asp
900 905 910
Leu Gln Phe Val Glu Val Thr Asp Val Lys Val Thr Ile Met Trp Thr
915 920 925
Pro Pro Glu Ser Ala Val Thr Gly Tyr Arg Val Asp Val Ile Pro Val
930 935 940
Asn Leu Pro Gly Glu His Gly Gln Arg Leu Pro Ile Ser Arg Asn Thr
945 950 955 960
Phe Ala Glu Val Thr Gly Leu Ser Pro Gly Val Thr Tyr Tyr Phe Lys
965 970 975
Val Phe Ala Val Ser His Gly Arg Glu Ser Lys Pro Leu Thr Ala Gln
980 985 990
Gln Thr Thr Lys Leu Asp Ala Pro Thr Asn Leu Gln Phe Val Asn Glu
995 1000 1005
Thr Asp Ser Thr Val Leu Val Arg Trp Thr Pro Pro Arg Ala Gln Ile
1010 1015 1020
Thr Gly Tyr Arg Leu Thr Val Gly Leu Thr Arg Arg Gly Gln Pro Arg
1025 1030 1035 1040
Gln Tyr Asn Val Gly Pro Ser Val Ser Lys Tyr Pro Leu Arg Asn Leu
1045 1050 1055
Gln Pro Ala Ser Glu Tyr Thr Val Ser Leu Val Ala Ile Lys Gly Asn
1060 1065 1070
Gln Glu Ser Pro Lys Ala Thr Gly Val Phe Thr Thr Leu Gln Pro Gly
1075 1080 1085
Ser Ser Ile Pro Pro Tyr Asn Thr Glu Val Thr Glu Thr Thr Ile Val
1090 1095 1100
Ile Thr Trp Thr Pro Ala Pro Arg Ile Gly Phe Lys Leu Gly Val Arg
1105 1110 1115 1120
Pro Ser Gln Gly Gly Glu Ala Pro Arg Glu Val Thr Ser Asp Ser Gly
1125 1130 1135
Ser Ile Val Val Ser Gly Leu Thr Pro Gly Val Glu Tyr Val Tyr Thr
1140 1145 1150
Ile Gln Val Leu Arg Asp Gly Gln Glu Arg Asp Ala Pro Ile Val Asn
1155 1160 1165
Lys Val Val Thr Pro Leu Ser Pro Pro Thr Asn Leu His Leu Glu Ala
1170 1175 1180
Asn Pro Asp Thr Gly Val Leu Thr Val Ser Trp Glu Arg Ser Thr Thr
1185 1190 1195 1200
Pro Asp Ile Thr Gly Tyr Arg Ile Thr Thr Thr Pro Thr Asn Gly Gln
1205 1210 1215
Gln Gly Asn Ser Leu Glu Glu Val Val His Ala Asp Gln Ser Ser Cys
1220 1225 1230
Thr Phe Asp Asn Leu Ser Pro Gly Leu Glu Tyr Asn Val Ser Val Tyr
1235 1240 1245
Thr Val Lys Asp Asp Lys Glu Ser Val Pro Ile Ser Asp Thr Ile Ile
1250 1255 1260
Pro Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Ile Thr Asp
1265 1270 1275 1280
Ser Ser Ile Gly Leu Arg Trp Thr Pro Leu Asn Ser Ser Thr Ile Ile
1285 1290 1295
Gly Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile Phe
1300 1305 1310
Glu Asp Phe Val Asp Ser Ser Val Gly Tyr Tyr Thr Val Thr Gly Leu
1315 1320 1325
Glu Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Asn Gly
1330 1335 1340
Gly Glu Ser Ala Pro Thr Thr Leu Thr Gln Gln Thr Ala Val Pro Pro
1345 1350 1355 1360
Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg Val
1365 1370 1375
Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu Val Arg
1380 1385 1390
Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu Ser Ile Ser
1395 1400 1405
Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu Pro Gly Thr Glu
1410 1415 1420
Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln His Glu Ser Thr Pro
1425 1430 1435 1440
Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp Ser Pro Thr Gly Ile Asp
1445 1450 1455
Phe Ser Asp Ile Thr Ala Asn Ser Phe Thr Val His Trp Ile Ala Pro
1460 1465 1470
Arg Ala Thr Ile Thr Gly Tyr Arg Ile Arg His His Pro Glu His Phe
1475 1480 1485
Ser Gly Arg Pro Arg Glu Asp Arg Val Pro His Ser Arg Asn Ser Ile
1490 1495 1500
Thr Leu Thr Asn Leu Thr Pro Gly Thr Glu Tyr Val Val Ser Ile Val
1505 1510 1515 1520
Ala Leu Asn Gly Arg Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser
1525 1530 1535
Thr Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro
1540 1545 1550
Thr Ser Leu Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr
1555 1560 1565
Tyr Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu
1570 1575 1580
Phe Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys
1585 1590 1595 1600
Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg Gly
1605 1610 1615
Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg Thr Glu
1620 1625 1630
Ile Asp Lys Pro Ser Gln Met Gln Val Thr Asp Val Gln Asp Asn Ser
1635 1640 1645
Ile Ser Val Lys Trp Leu Pro Ser Ser Ser Pro Val Thr Gly Tyr Arg
1650 1655 1660
Val Thr Thr Thr Pro Lys Asn Gly Pro Gly Pro Thr Lys Thr Lys Thr
1665 1670 1675 1680
Ala Gly Pro Asp Gln Thr Glu Met Thr Ile Glu Gly Leu Gln Pro Thr
1685 1690 1695
Val Glu Tyr Val Val Ser Val Tyr Ala Gln Asn Pro Ser Gly Glu Ser
1700 1705 1710
Gln Pro Leu Val Gln Thr Ala Val Thr Asn Ile Asp Arg Pro Lys Gly
1715 1720 1725
Leu Ala Phe Thr Asp Val Asp Val Asp Ser Ile Lys Ile Ala Trp Glu
1730 1735 1740
Ser Pro Gln Gly Gln Val Ser Arg Tyr Arg Val Thr Tyr Ser Ser Pro
1745 1750 1755 1760
Glu Asp Gly Ile His Glu Leu Phe Pro Ala Pro Asp Gly Glu Glu Asp
1765 1770 1775
Thr Ala Glu Leu Gln Gly Leu Arg Pro Gly Ser Glu Tyr Thr Val Ser
1780 1785 1790
Val Val Ala Leu His Asp Asp Met Glu Ser Gln Pro Leu Ile Gly Thr
1795 1800 1805
Gln Ser Thr Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val
1810 1815 1820
Thr Pro Thr Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu
1825 1830 1835 1840
Thr Gly Tyr Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met
1845 1850 1855
Lys Glu Ile Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly
1860 1865 1870
Leu Met Val Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp
1875 1880 1885
Thr Leu Thr Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn
1890 1895 1900
Val Ser Pro Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr
1905 1910 1915 1920
Ile Thr Ile Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln
1925 1930 1935
Val Asp Ala Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile
1940 1945 1950
Lys Pro Asp Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr
1955 1960 1965
Asp Tyr Lys Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser
1970 1975 1980
Pro Val Val Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu
1985 1990 1995 2000
Arg Phe Leu Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro
2005 2010 2015
Pro Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Lys Pro Gly
2020 2025 2030
Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu
2035 2040 2045
Ala Thr Ile Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val
2050 2055 2060
Ile Ala Leu Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys
2065 2070 2075 2080
Lys Thr Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu
2085 2090 2095
His Gly Pro Glu Ile Leu Asp Val Pro Ser Thr Val Gln Lys Thr Pro
2100 2105 2110
Phe Val Thr His Pro Gly Tyr Asp Thr Gly Asn Gly Ile Gln Leu Pro
2115 2120 2125
Gly Thr Ser Gly Gln Gln Pro Ser Val Gly Gln Gln Met Ile Phe Glu
2130 2135 2140
Glu His Gly Phe Arg Arg Thr Thr Pro Pro Thr Thr Ala Thr Pro Ile
2145 2150 2155 2160
Arg His Arg Pro Arg Pro Tyr Pro Pro Asn Val Gly Gln Glu Ala Leu
2165 2170 2175
Ser Gln Thr Thr Ile Ser Trp Ala Pro Phe Gln Asp Thr Ser Glu Tyr
2180 2185 2190
Ile Ile Ser Cys His Pro Val Gly Thr Asp Glu Glu Pro Leu Gln Phe
2195 2200 2205
Arg Val Pro Gly Thr Ser Thr Ser Ala Thr Leu Thr Gly Leu Thr Arg
2210 2215 2220
Gly Ala Thr Tyr Asn Val Ile Val Glu Ala Leu Lys Asp Gln Gln Arg
2225 2230 2235 2240
His Lys Val Arg Glu Glu Val Val Thr Val Gly Asn Ser Val Asn Glu
2245 2250 2255
Gly Leu Asn Gln Pro Thr Asp Asp Ser Cys Phe Asp Pro Tyr Thr Val
2260 2265 2270
Ser His Tyr Ala Val Gly Asp Glu Trp Glu Arg Met Ser Glu Ser Gly
2275 2280 2285
Phe Lys Leu Leu Cys Gln Cys Leu Gly Phe Gly Ser Gly His Phe Arg
2290 2295 2300
Cys Asp Ser Ser Arg Trp Cys His Asp Asn Gly Val Asn Tyr Lys Ile
2305 2310 2315 2320
Gly Glu Lys Trp Asp Arg Gln Gly Glu Asn Gly Gln Met Met Ser Cys
2325 2330 2335
Thr Cys Leu Gly Asn Gly Lys Gly Glu Phe Lys Cys Asp Pro His Glu
2340 2345 2350
Ala Thr Cys Tyr Asp Asp Gly Lys Thr Tyr His Val Gly Glu Gln Trp
2355 2360 2365
Gln Lys Glu Tyr Leu Gly Ala Ile Cys Ser Cys Thr Cys Phe Gly Gly
2370 2375 2380
Gln Arg Gly Trp Arg Cys Asp Asn Cys Arg Arg Pro Gly Gly Glu Pro
2385 2390 2395 2400
Ser Pro Glu Gly Thr Thr Gly Gln Ser Tyr Asn Gln Tyr Ser Gln Arg
2405 2410 2415
Tyr His Gln Arg Thr Asn Thr Asn Val Asn Cys Pro Ile Glu Cys Phe
2420 2425 2430
Met Pro Leu Asp Val Gln Ala Asp Arg Glu Asp Ser Arg Glu
2435 2440 2445

Claims (3)

1.检测与遗传性肾小球疾病相关的突变基因FN1的试剂在制备纤维连接蛋白肾小球病检测试剂盒中的应用,其特征在于,突变基因FN1的核苷酸序列为SEQ ID NO:3,与野生型FN1基因编码DNA的参考序列相比,在基因组位置chr2:216273077处,碱基A突变为碱基G;参考基因组版本是GRCh37。
2.根据权利要求1所述的应用,其特征在于,所述纤维连接蛋白肾小球病检测试剂盒包括引物SEQ ID NO:1和SEQ ID NO:2。
3.根据权利要求2所述的应用,其特征在于,所述纤维连接蛋白肾小球病检测试剂盒还包括Taq DNA聚合酶和PCR缓冲液。
CN202111382255.5A 2021-11-22 2021-11-22 与遗传性肾小球疾病相关的突变基因及其应用 Active CN114085900B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111382255.5A CN114085900B (zh) 2021-11-22 2021-11-22 与遗传性肾小球疾病相关的突变基因及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111382255.5A CN114085900B (zh) 2021-11-22 2021-11-22 与遗传性肾小球疾病相关的突变基因及其应用

Publications (2)

Publication Number Publication Date
CN114085900A CN114085900A (zh) 2022-02-25
CN114085900B true CN114085900B (zh) 2022-07-29

Family

ID=80302373

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111382255.5A Active CN114085900B (zh) 2021-11-22 2021-11-22 与遗传性肾小球疾病相关的突变基因及其应用

Country Status (1)

Country Link
CN (1) CN114085900B (zh)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110885830A (zh) * 2018-09-07 2020-03-17 安徽华大医学检验所有限公司 Fn1基因突变及其应用

Also Published As

Publication number Publication date
CN114085900A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
CN109790583B (zh) 对肺腺癌亚型分型的方法
KR20140044341A (ko) 암에 대한 분자적 진단 검사
CN107760779B (zh) 肺动脉高压相关的突变型bmp9基因及其应用
KR20110057188A (ko) 바이오마커 프로파일 측정 시스템 및 방법
CN113981066B (zh) 突变的扩张型心肌病致病基因ttn及其应用
CA2568967A1 (en) Agents and methods for diagnosing stress
CN114107312B (zh) 突变的肥厚型心肌病致病基因mybpc3及其应用
Juuti-Uusitalo et al. cDNA microarray analysis of gene expression in coeliac disease jejunal biopsy samples
CN113832159A (zh) 突变的家族遗传性肺动脉高压致病基因bmpr2及其应用
CN114703278A (zh) 一种肌萎缩侧索硬化致病基因、检测试剂盒及引物组
CN113981065A (zh) 具有c.223dupG杂合错义的肥厚型心肌病致病基因MYBPC3及其应用
CN114836531A (zh) 一种用于检测类孟买血型变异型的snp位点
CN113980971B (zh) 突变的马凡综合征致病基因fbn1及其应用
JP2009500010A (ja) ネコアレルゲン
CN114085900B (zh) 与遗传性肾小球疾病相关的突变基因及其应用
CN113957075B (zh) 突变的遗传性心律失常基因及其应用
CN104419748B (zh) 利用基因型检测强直性脊柱炎易感性的方法和试剂盒
CN114107482A (zh) 肺动脉高压突变基因及其应用
CN113913437A (zh) 家族性胸主动脉瘤突变基因及其应用
CN113969313A (zh) 罕见遗传病突变基因及其应用
CN113957138B (zh) 与罕见遗传病有关的突变基因及其应用
CN114214398B (zh) 突变的fbn1基因及马凡氏综合征检测试剂盒
Swanberg et al. Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes
KR100976005B1 (ko) 만성 류마티스관절염 질환 감수성 유전자, 이의 단백질,이들을 이용한 만성 류마티스관절염의 발증가능성의 판정방법 및 판정 키트, 및 만성 류마티스관절염의 치료 방법및 치료 약제
KR102064895B1 (ko) Hla 유전형 검사를 이용한 자가면역성 뇌염 타입 판별 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant